TLR7 and influenza: In this work we sought to augment the PNP hydrogel delivery platform for sustained co‐delivery of the influenza antigen hemagglutinin (HA), the most common antigen in standard influenza subunit vaccines, with a potent TLR7/8a adjuvant that has previously been shown to elicit strong titers against HA and has demonstrated promise for clinical translation in influenza vaccination.38